ClinicalTrials.gg
RecruitingNCT07621692Updated Jun 2, 2026

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

A Phase 1 interventional study of 161Tb-PSMA-I&T in Metastatic Castration Resistant Prostate Cancer (mCRPC), sponsored by National Taiwan University Hospital. Recruiting at 2 sites in Taiwan. Open to male participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by National Taiwan University Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
20 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Prostatic Neoplasms by National Taiwan University Hospital — 7 open to participants now, 7 under way, none of them phase 3. Prostatic Neoplasms · National Taiwan University Hospital.

Started
2026
the only one that year
Phase 1
Only one
of the 16
Registered
16th of 16
by date

Among the 16 studies in Prostatic Neoplasms by National Taiwan University Hospital, this one is the only one that started in 2026, is the only one in phase 1, and was the 16th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 16 studies in Prostatic Neoplasms by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 20 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Prostatic Neoplasms by National Taiwan University Hospital, or all of them as a file.
02

Study summary

This study is a phase I dose escalation clinical trial aims to evaluate 161Tb-PSMA-I\&T, a new generation prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) using Terbium-161 to replace Lutetium-177, its safety, dosimetry, biodistribution, pharmacokinetics, and preliminary efficacy in Taiwanese men with metastatic castration-resistant prostate cancer, and to inform future clinical trials.

Read the detailed description

Metastatic castration-resistant prostate cancer (mCRPC) represents the most advanced and treatment-refractory form of prostate cancer, where disease progression continues despite hormone-suppressing therapies and multiple lines of systemic treatment. Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) has emerged as a promising treatment strategy, delivering targeted radiation to cancer cells using PSMA-binding ligands labeled with therapeutic radioisotopes. While Lutetium-177 (177Lu)-labeled compounds such as 177Lu-PSMA-617 have demonstrated meaningful clinical benefit, their effectiveness may be limited in cases of micrometastatic disease or heterogeneous PSMA expression, due to the physical characteristics of longer-range β particle radiation.

Terbium-161 (161Tb) is a next-generation radionuclide that emits not only β particles but also short-range, high-linear energy transfer Auger electrons. This dual emission profile enables more effective cell killing in small or poorly perfused tumor sites, with potentially enhanced tumor-to-normal tissue selectivity. Preclinical studies and early case reports suggest that 161Tb-labeled PSMA agents may offer superior tumor dosimetry and cytotoxicity compared to 177Lu analogs. Most notably, the recently published VIOLET Phase I/II trial-the largest clinical experience with 161Tb-PSMA-I\&T to date-demonstrated favorable safety across escalating doses (up to 7.4 GBq) and promising therapeutic activity. These findings confirm that 161Tb-PSMA RLT is both safe and clinically active, even in patients previously treated with 177Lu-based agents.

Building on this foundation, our study aims to establish a standardized GMP-grade production process for 161Tb-PSMA-I\&T and to evaluate its pharmacokinetics, biodistribution, and radiation dosimetry in a small cohort of Taiwanese patients with mCRPC. These pilot data will generate critical clinical insight and infrastructure, directly informing the design of future Phase Ib/II trials and accelerating national readiness for next-generation PSMA-targeted therapies, especially emphasizing on three specific aims: (1) to establish a GMP-compliant manufacturing process for clinical-grade 161Tb-PSMA-I\&T suitable for clinical application in Taiwan; (2) to characterize 161Tb-PSMA-I\&T focusing on its pharmacokinetics, biodistribution, and radiation dosimetry; (3) to explore preliminary safety data of 161Tb-PSMA-I\&T using potential treatment doses in Asian population.

03

Conditions studied

  • Metastatic Castration Resistant Prostate Cancer (mCRPC)

Browse trials for

Keywords

  • Radioligand therapy
  • Terbium-161
  • Prostate-specific Membrane Antigen (PSMA)
  • Metastatic Castration Resistant Prostate Cancer (mCRPC)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 20 years, ability to understand and willingness to sign , cooperate with all study-related procedures and assessments including blood tests and imaging
  2. confirmed adenocarcinoma of the prostate with evidence of castration-resistant prostate cancer (mCRPC)
  3. Prior surgical orchiectomy or chemical castration maintained on luteinizing hormone-releasing hormone analog, with a serum testosterone level \<50 ng/dL (castrate range)
  4. Prior treated with at least one line of taxane-based chemotherapy unless medically unsuitable, and at least one line of androgen receptor pathway inhibitor (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide)
  5. Prior treated with 177Lu-labeled PSMA RLT unless medically unsuitable or declined by the patient
  6. Progressive disease defined according to Prostate Cancer Clinical Trials Working Group 3: Either a PSA progression of more than 2 rising PSA values from baseline with intervals ≥ 1 week, or a soft-tissue progression on images per 1.1 criteria, or a bone progression on images with more than 2 new lesions
  7. Evidence of significant PSMA-avid lesions on 68Ga- or 18F-labeled PSMA PET/CT within 12 weeks prior to screening, which defined as 68Ga-PSMA or 18F-PSMA uptake greater than that of liver or spleen parenchyma (depend on the tracer used) in at least one metastatic lesion of any size in any organ system
  8. A of ≥ 6 months and (ECOG) performance status of 0-2
  9. Adequate bone marrow and organ functions 9.1 ≥ 10 g/dL without RBC transfusion within 4 weeks 9.2 ≥ 1.5 × 109/L 9.3 count ≥ 150 × 109/L 9.4 ≥ 50 mL/min (Cockcroft-Gault) 9.5 and ALT ≤ 3 × , total ≤ 1.5 × ULN
  10. Willingness to comply with the use of medically acceptable forms of barrier if sexually active

Exclusion criteria

Exclusion Criteria:

  1. History of allergic reaction to PSMA-targeted compounds or radiometals
  2. Prior radioligand therapy with 223Ra or 177Lu-PSMA within 6 months
  3. Prior surgery or radiotherapy within 4 weeks prior to first dose
  4. Prior systemic therapies against prostate cancer within 4 weeks, including androgen receptor pathway inhibitor, chemotherapy, targeted therapy such as PARP inhibitors (PARPi)
  5. Discordant disease on PET images: FDG-positive disease with minimal PSMA expression
  6. Urinary tract obstruction causing hydronephrosis unless appropriately treated beforehand
  7. Known symptomatic or , symptomatic or impending cord compression unless appropriately treated beforehand
  8. Other active requiring systemic treatment
  9. Significant cardiovascular disease (e.g., recent myocardial infarction, unstable angina)
  10. Concurrent severe uncontrolled illness that may jeopardize patient safety, including uncontrolled infections
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Dose level 1

    120 mCi of 161Tb-PSMA-I\&T every 6 weeks for 3 cycles

    Drug: 161Tb-PSMA-I&T

  • Experimental
    Dose level 2

    150 mCi of 161Tb-PSMA-I\&T every 6 weeks for 3 cycles

    Drug: 161Tb-PSMA-I&T

  • Experimental
    Dose level 3

    200 mCi of 161Tb-PSMA-I\&T every 6 weeks for 3 cycles

    Drug: 161Tb-PSMA-I&T

Interventions

  • Drug161Tb-PSMA-I&T

    161Tb-PSMA-I\&T for injections, slow intravenous administration, 200 mCi/5 mL/Vial

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events

    Incidence, nature, and severity of treatment-emergent adverse events (TEAEs) graded by CTCAE v5.0 across the entire treatment and 18-week post-treatment surveillance period

    Time frame: From enrollment to the end of post-treatment surveillance, at least 36 weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2030, 59 months after the start.

Of 243 non-industry phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's planned 59 months is above that.

Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Jun 2, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07621692
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jan 1, 2026
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jun 2, 2026

Study contacts

Pei-Ju Chuang
Contact
pjchuang.ntucc@gmail.com
+886-2-2322-0322 ext. 237966
Ching-Chu Lu
Contact
kelvinlu@ntuh.gov.tw
+886-2-2312-3456 ext. 265477
Ching-Chu Lu
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion